Hepion Pharmaceuticals acquires Gravitas Life Sciences for $2M cash
Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences under a Membership Interest Purchase Agreement, paying $2.0 million in cash, issuing 25 million shares subject to a 19.99% issuance cap, and paying an additional $135,000 cash.
0 million in cash and issuing 25 million shares. 99% issuance cap and an additional $135,000 cash payment. The Buyer Closing Shares are locked up until further notice.